ArticleOncoimmunology2020
Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications.Scientific reports · 2025Article
- A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Development and Assessment of a Prediction Model for Alzheimer's Disease Diagnosis Based on Thermoregulation-Related Genes.Combinatorial chemistry & high throughput screening · 2025Article
- Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.Biology direct · 2024Article
- Predictive model of gene expression regulating invasion and migration of M2 macrophages in breast cancer: clinical prognosis and therapeutic implications.Translational cancer research · 2024Article
- Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Integrating somatic CNV and gene expression in breast cancers from women with PTEN hamartoma tumor syndrome.NPJ genomic medicine · 2023Article
- ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer.Frontiers in oncology · 2023Article
- An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.Scientific reports · 2022Article
- A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers.Scientific data · 2022Article
- Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.JCI insight · 2022Article
- An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Cancer science · 2022Article
- Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 inFrontiers in oncology · 2022Article
- Construction and Validation of a Newly Prognostic Signature for CRISPR-Cas9-Based Cancer Dependency Map Genes in Breast Cancer.Journal of oncology · 2022Article
- Article
- RNA binding motif 47 (RBM47): emerging roles in vertebrate development, RNA editing and cancer.Molecular and cellular biochemistry · 2021Review
- A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021Article
- Article
- Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC.Molecular therapy. Nucleic acids · 2021Article
- Comprehensive Analysis of Immune Implication and Prognostic Value ofFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is characterized by broad genomic and transcriptional heterogeneity and results in a worse prognosis than other breast cancer types. Here, we integrated genomic and transcriptomic data combined with clinicopathologic information from 538 patients with TNBC and identified four novel significantly mutated genes (SMGs), namely,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.